NANBIOSIS attended MedTech Forum 2026 in Stockholm, strengthening international collaborations and exploring the latest trends in medtech innovation
Stockholm, May 2026 — Last week, from 11 to 13 May 2026, NANBIOSIS participated in the MedTech Forum 2026, one of Europe’s leading conferences for the medical technology sector, held in Stockholm, Sweden.
The event brought together industry leaders, researchers, healthcare professionals, regulators, and innovators to discuss the future of medical technologies, artificial intelligence, digital health, sustainability, regulatory challenges, and healthcare resilience. During the forum, NANBIOSIS established valuable contacts with international partners and explored new opportunities for collaboration in biomedical innovation and technology transfer.
The programme featured high-level sessions on topics such as AI in healthcare, European regulatory frameworks for medical devices, health data sharing, sustainability in medtech, and strategies to strengthen Europe’s healthcare resilience and competitiveness. Among the key themes discussed were the implementation of the European Health Data Space (EHDS), the evolution of MDR and IVDR regulations, and the growing role of AI-enabled medical technologies.
Participation in MedTech Forum 2026 reinforces NANBIOSIS’ commitment to supporting cutting-edge biomedical research infrastructures and fostering international partnerships that accelerate innovation in healthcare technologies.
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
If you want to collaborate with us, visit our Order Request page.
Leading scientists
The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.
Custom solutions
Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities
Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.
Standards of quality
Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:








